Breaching the castle walls: Hyaluronan depletion as a therapeutic approach to cancer therapy

Frontiers in Oncology

Volumn 5, Issue Aug, 2015, Pages

  Shepard, H Michael ^a  

^a Halozyme Therapeutics Inc   (United States)

Author keywords

Extracellular matrix; Hyaluronan; Hyaluronidase; Interstitial fluid pressure; PEGPH20; Treatment resistance; Tumor microenvironment

Indexed keywords

CALCIPOTRIOL; CD147 ANTIGEN; DOXORUBICIN; GEMCITABINE; HYALURONIC ACID; HYALURONIDASE; HYALURONIDASE 1; HYALURONIDASE 2; HYALURONIDASE 3; HYALURONIDASE 4; PEGYLATED HYALURONIDASE; PENTRAXIN 3; PROTEIN TYROSINE KINASE; RECOMBINANT HYALURONIDASE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; ASTROCYTOMA; CANCER THERAPY; CELL INTERACTION; DRUG EFFICACY; EXTRACELLULAR MATRIX; HUMAN; NATURAL KILLER CELL; NONHUMAN; PANCREAS CANCER; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCANNING ELECTRON MICROSCOPY; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84941004170     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00192     Document Type: Article

References (73)

1. Meyer K, Palmer J. The polysaccharide of the vitreous humor. J Biol Chem (1934) 107:629-34.
2. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer (2004) 4(7):528-39. doi: 10.1038/nrc1391.
3. Hascall V, Esko JD. Hyaluronan. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. Essentials of Glycobiology, Chapter 15, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press (2009).
4. Cowman MK, Matsuoka S. Experimental approaches to hyaluronan structure. Carbohydr Res (2005) 340(5):791-809. doi:10.1016/j.carres.2005.01.022.
5. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release (2006) 114(2):230-41. doi:10.1016/j.jconrel.2006.05.027.
6. Kultti A, Li X, Jiang P, Thompson CB, Frost GI, Shepard HM. Therapeutic targeting of hyaluronan in the tumor stroma. Cancers (Basel) (2012) 4(3):873-903. doi:10.3390/cancers4030873.
7. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol (2000) 156(2):529-36. doi:10.1016/S0002-9440(10)64757-8.
8. Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV, Kosma VM. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res (2000) 60(1):150-5.
9. Auvinen P, Tammi R, Kosma VM, Sironen R, Soini Y, Mannermaa A, et al. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer (2013) 132(3):531-9. doi:10.1002/ijc.27707.
10. Boregowda RK, Appaiah HN, Siddaiah M, Kumarswamy SB, Sunila S, Thimmaiah KN, et al. Expression of hyaluronan in human tumor progression. J Carcinog (2006) 5:2. doi:10.1186/1477-3163-5-2.
11. Pirinen R, Tammi R, Tammi M, Hirvikoski P, Parkkinen JJ, Johansson R, et al. Prognostic value of hyaluronan expression in non-small-cell lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer (2001) 95(1):12-7. doi:10.1002/1097-0215(20010120)95:1<12::AID-IJC1002>3.3.CO;2-5.
12. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P, et al. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res (1998) 58(2):342-7.
13. Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M, Kosma VM. Hyaluronan in human malignancies. Exp Cell Res (2011) 317(4):383-91. doi:10.1016/j.yexcr.2010.11.017.
14. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J (2010) 277(19):3904-23. doi:10.1111/j.1742-4658.2010.07800.x.
15. Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res (2015) 21(15):3561-8. doi:10.1158/1078-0432.CCR-14-1051.
16. Thompson CB, Shepard HM, O'Connor PM, Kadhim S, Jiang P, Osgood RJ, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther (2010) 9(11):3052-64. doi:10.1158/1535-7163.MCT-10-0470.
17. Kultti A, Zhao C, Singha NC, Zimmerman S, Osgood RJ, Symons R, et al. Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment. Biomed Res Int (2014) 2014:817613. doi:10.1155/2014/817613.
18. Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giant. J Biol Chem (2002) 277(7):4585-8. doi:10.1074/jbc.R100036200.
19. Rilla K, Siiskonen H, Tammi M, Tammi R. Hyaluronan-coated extracellular vesicles-a novel link between hyaluronan and cancer. Adv Cancer Res (2014) 123:121-48. doi:10.1016/B978-0-12-800092-2.00005-8.
20. Dicker KT, Gurski LA, Pradhan-Bhatt S, Witt RL, Farach-Carson MC, Jia X. Hyaluronan: a simple polysaccharide with diverse biological functions. Acta Biomater (2014) 10(4):1558-70. doi:10.1016/j.actbio.2013.12.019.
21. Baranova NS, Inforzato A, Briggs DC, Tilakaratna V, Enghild JJ, Thakar D, et al. Incorporation of pentraxin 3 into hyaluronan matrices is tightly regulated and promotes matrix cross-linking. J Biol Chem (2014) 289(44):30481-98. doi:10.1074/jbc.M114.568154.
22. Kondo S, Ueno H, Hosoi H, Hashimoto J, Morizane C, Koizumi F, et al. Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. Br J Cancer (2013) 109(3):739-46. doi:10.1038/bjc.2013.348.
23. Lim JJ, Temenoff JS. The effect of desulfation of chondroitin sulfate on interactions with positively charged growth factors and upregulation of cartilaginous markers in encapsulated MSCs. Biomaterials (2013) 34(21):5007-18. doi:10.1016/j.biomaterials.2013.03.037.
24. Jiang P, Li X, Thompson CB, Huang Z, Araiza F, Osgood R, et al. Effective targeting of the tumor microenvironment for cancer therapy. Anticancer Res (2012) 32(4):1203-12.
25. Provenzano PP, Inman DR, Eliceiri KW, Keely PJ. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene (2009) 28(49):4326-43. doi:10.1038/onc.2009.299.
26. Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev (2009) 28(1-2):113-27. doi:10.1007/s10555-008-9173-4.
27. Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI. Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol (2008) 18(4):288-95. doi:10.1016/j.semcancer.2008.03.005.
28. Nagy N, Kuipers HF, Frymoyer AR, Ishak HD, Bollyky JB, Wight TN, et al. 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol (2015) 6:123. doi:10.3389/fimmu.2015.00123.
29. McBride WH, Bard JB. Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis. J Exp Med (1979) 149(2):507-15.
30. Varadi T, Mersich T, Auvinen P, Tammi R, Tammi M, Salamon F, et al. Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan. J Histochem Cytochem (2012) 60(8):567-75. doi:10.1369/0022155412448070.
31. Singha NC, Nekoroski T, Zhao C, Symons R, Jiang P, Frost GI, et al. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. Mol Cancer Ther (2015) 14(2):523-32. doi:10.1158/1535-7163.MCT-14-0580.
32. Sohr S, Engeland K. RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle (2008) 7(21):3448-60. doi:10.4161/cc.7.21.7014.
33. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 134(1):62-73. doi:10.1016/j.cell.2008.06.006.
34. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol (2003) 4(1):33-45. doi:10.1038/nrm1004.
35. Grass GD, Dai L, Qin Z, Parsons C, Toole BP. CD147: regulator of hyaluronan signaling in invasiveness and chemoresistance. Adv Cancer Res (2014) 123:351-73. doi:10.1016/B978-0-12-800092-2.00013-7.
36. Toole BP. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res (2009) 15(24):7462-8. doi:10.1158/1078-0432.CCR-09-0479.
37. Hudziak RM, Lewis GD, Shalaby MR, Eessalu TE, Aggarwal BB, Ullrich A, et al. Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc Natl Acad Sci U S A (1988) 85(14):5102-6. doi:10.1073/pnas.85.14.5102.
38. Simpson RM, Wells A, Thomas D, Stephens P, Steadman R, Phillips A. Aging fibroblasts resist phenotypic maturation because of impaired hyaluronan-dependent CD44/epidermal growth factor receptor signaling. Am J Pathol (2010) 176(3):1215-28. doi:10.2353/ajpath.2010.090802.
39. Slomiany MG, Dai L, Tolliver LB, Grass GD, Zeng Y, Toole BP. Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin Cancer Res (2009) 15(24):7593-601. doi:10.1158/1078-0432.CCR-09-2317.
40. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2013) 62(1):112-20. doi:10.1136/gutjnl-2012-302529.
41. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 21(3):418-29. doi:10.1016/j.ccr.2012.01.007.
42. Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, et al. Exploratory biomarker results from early investigation of PEGPH20 in combination with gemcitabine in patients with pancreatic cancer. Presented at the American Society of Clinical Oncology Gastrointestinal Symposium; 2015 January 15-17. San Francisco, CA (2015). Abstract 300.
43. Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front Immunol (2015) 6:201. doi:10.3389/fimmu.2015.00201.
44. Thomas N, Waltham M, Udabage L, Brown T. Hyaluronan metabolism enhances the Warburg effect and provides an alternate energy source in the breast cancer microenvironment. Presented at the American Association for Cancer Research Annual Meeting; 2010 April 17-21. Washington, DC (2010). Abstract 58.
45. Ramanathan R, Infante JR, Rosen L, Von Hoff D, Dychter S, Shepard HM, et al. Targeting hyaluronan in tumor stroma: interim translational & biomarker evaluations of pegylated hyaluronidase (PEGPH20) in patients with advanced solid tumors. Presented at the EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer; 2011 October 27-29. Brussels (2011). Abstract 60.
46. Jacobson A, Rahmanian M, Rubin K, Heldin P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer (2002) 102(3):212-9. doi:10.1002/ijc.10683.
47. Li Y, Heldin P. Hyaluronan production increases the malignant properties of mesothelioma cells. Br J Cancer (2001) 85(4):600-7. doi:10.1054/bjoc.2001.1922.
48. Zoltan-Jones A, Huang L, Ghatak S, Toole BP. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem (2003) 278(46):45801-10. doi:10.1074/jbc.M308168200.
49. Jadin L, Pastorino S, Symons R, Nomura N, Jiang P, Juarez T, et al. Hyaluronan expression in primary and secondary brain tumors. Ann Transl Med (2015) 3(6):80. doi:10.3978/j.issn.2305-5839.2015.04.07.
50. Pillwein K, Fuiko R, Slavc I, Czech T, Hawliczek G, Bernhardt G, et al. Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors. Cancer Lett (1998) 131(1):101-8. doi:10.1016/S0304-3835(98)00205-5.
51. Baumgartner G, Gomar-Hoss C, Sakr L, Ulsperger E, Wogritsch C. The impact of extracellular matrix on the chemoresistance of solid tumors-experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett (1998) 131(1):85-99. doi:10.1016/S0304-3835(98)00204-3.
52. Klocker J, Sabitzer H, Raunik W, Wieser S, Schumer J. Hyaluronidase as additive to induction chemotherapy in advanced squamous cell carcinoma of the head and neck. Cancer Lett (1998) 131(1):113-5. doi:10.1016/S0304-3835(98)00207-9.
53. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv (2007) 4(4):427-40. doi:10.1517/17425247.4.4.427.
54. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol (2012) 22(5-6):396-403. doi:10.1016/j.semcancer.2012.04.001.
55. Singleton PA. Hyaluronan regulation of endothelial barrier function in cancer. Adv Cancer Res (2014) 123:191-209. doi:10.1016/B978-0-12-800092-2.00007-1.
56. Manuel E, Chen J, D'Apuzzo M, Lampa M, Kaltcheva T, Thompson C, et al. Salmonella-based therapy targeting indoleamine 2,3-dioxygenase coupled with enzymatic depletion of tumor hyaluronan induces complete regression of aggressive pancreatic tumors. Cancer Immunol Res (2015). doi:10.1158/2326-6066.CIR-14-0214.
57. Nakazawa H, Yoshihara S, Kudo D, Morohashi H, Kakizaki I, Kon A, et al. 4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells. Cancer Chemother Pharmacol (2006) 57(2):165-70. doi:10.1007/s00280-005-0016-5.
58. Piccioni F, Fiore E, Bayo J, Atorrasagasti C, Peixoto E, Rizzo M, et al. 4-Methylumbelliferone inhibits hepatocellular carcinoma growths by decreasing IL-6 production and angiogenesis. Glycobiology (2015) 25(8):825-35. doi:10.1093/glycob/cwv023.
59. Kultti A, Karna R, Rilla K, Nurminen P, Koli E, Makkonen KM, et al. Methyl-beta-cyclodextrin suppresses hyaluronan synthesis by down-regulation of hyaluronan synthase 2 through inhibition of Akt. J Biol Chem (2010) 285(30):22901-10. doi:10.1074/jbc.M109.088435.
60. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res (1999) 59(15): 3776-82.
61. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell (2014) 159(1):80-93. doi:10.1016/j.cell.2014.08.007.
62. Vigetti D, Genasetti A, Karousou E, Viola M, Moretto P, Clerici M, et al. Proinflammatory cytokines induce hyaluronan synthesis and monocyte adhesion in human endothelial cells through hyaluronan synthase 2 (HAS2) and the nuclear factor-kappaB (NF-kappaB) pathway. J Biol Chem (2010) 285(32):24639-45. doi:10.1074/jbc.M110.134536.
63. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol (2001) 20(8):499-508. doi:10.1016/S0945-053X(01)00172-X.
64. Stern R. Hyaluronidases in cancer biology. Semin Cancer Biol (2008) 18(4):275-80. doi:10.1016/j.semcancer.2008.03.017.
65. Nikitovic D, Kouvidi K, Voudouri K, Berdiaki A, Karousou E, Passi A, et al. The motile breast cancer phenotype roles of proteoglycans/glycosaminoglycans. Biomed Res Int (2014) 2014:124321. doi:10.1155/2014/124321.
66. Lokeshwar VB, Mirza S, Jordan A. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res (2014) 123:35-65. doi:10.1016/B978-0-12-800092-2.00002-2.
67. Roden L, Campbell P, Fraser JR, Laurent TC, Pertoft H, Thompson JN. Enzymic pathways of hyaluronan catabolism. Ciba Found Symp (1989) 143:60-76.
68. Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer (2013) 12:152. doi:10.1186/1476-4598-12-152.
69. Harada H, Takahashi M. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and-2. J Biol Chem (2007) 282(8):5597-607. doi:10.1074/jbc.M608358200.
70. Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, et al. A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. Presented at the American Society of Clinical Oncology Annual Meeting; 2013 May 31-June 4. Chicago, IL (2013). Abstract 4010.
71. Jadin L, Huang L, Zhao Q, Wei G, Shepard M, Gelb A, et al. Development of a Companion Diagnostic for Pegylated Recombinant Human PH20. Boston, MA: EORTC (2013) Abstract MC13-0055.
72. S1313, a Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma. Accessed from https://clinicaltrials.gov/ct2/show/NCT01959139.
73. A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with Nab-Paclitaxel Plus Gemcitabine Compared with Nab-Paclitaxel Plus Gemcitabine in Subjects with Stage IV Previously Untreated Pancreatic Cancer. Accessed from: http://clinicaltrials.gov/ct2/show/NCT01839487.